Drugs / TOOKAD Soluble
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03315754 | Oct 2017 → Nov 2020 overdue | — | Steba Biotech S.A. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01875393 | May 2013 → Dec 2014 | prostate cancer | Steba Biotech S.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOOKAD Soluble | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03315754 ↗ |
| Route | Intravenous | “received a 10-min intravenous infusion of a single dose of 4 mg/kg TOOKAD(®) Soluble” PMID 25712310 ↗ Feb 2015 |